Are Exosomes the Future of Regenerative Medicine—or Has the Hype Gotten Ahead of the Science?
PRP. Stem cells. Peptides. Now exosomes.
Regenerative medicine is moving fast—and patients are spending thousands of dollars hoping to avoid surgery, recover faster, regenerate damaged joints, and stay active longer. But there’s a problem: not every exosome treatment is the same, and many patients don’t actually know what they’re buying.
That’s exactly why we brought Dr. Jeff Gross back to the Crackin’ Backs Podcast.
Meet Dr. Jeff Gross
Dr. Jeff Gross is a neurosurgeon, spinal biomechanics specialist, and regenerative medicine physician whose work has expanded beyond traditional surgery into biologics, longevity, joint preservation, and less-invasive strategies for musculoskeletal recovery.
What makes this conversation different is that Gross doesn’t simply ask, “Do exosomes work?”
He asks the harder questions:
Where did they come from? How many are there? What is actually in the product? Where are they being placed? And is the patient biologically prepared to heal?
That distinction matters because, as Gross explains, being told you received “five milliliters of exosomes” tells you almost nothing about the actual product.
What Are Exosomes?
Exosomes are tiny extracellular vesicles involved in cell-to-cell communication.
Cells release them carrying signaling molecules that can include proteins, lipids, growth factors, and RNA. Other cells can then take up those signals.
Gross describes exosomes as part of the communication system through which stem cells influence surrounding tissue.
That idea has helped make stem-cell-derived exosomes one of the most talked-about areas in regenerative medicine.
But excitement and evidence are not the same thing.
Research into extracellular vesicles is expanding rapidly, but many clinical applications discussed in private regenerative medicine practices remain not yet FDA-approved treatments (for marketing claims) for orthopedic, neurologic, autoimmune, or longevity conditions.
That makes informed decision-making critical.
The Biggest Mistake Patients Make
According to Gross, patients often focus on the wrong number.
They ask:
“How many milliliters did I get?”
He argues that volume alone is essentially meaningless.
Instead, he says patients should be asking about:
Particle count
Source
Processing
Storage
Size distribution
Protein content
Sterility and endotoxin testing
Certificate of analysis
In other words:
You shouldn’t shop for exosomes by volume any more than you’d buy a medication without knowing the dose.
5 Key Insights From This Episode
1. More Isn’t Automatically Better
The regenerative medicine world often assumes that a bigger dose must produce a better result.
Gross pushes back on that thinking.
Particle count, biological quality, source, and targeting may matter far more than the number of milliliters in the syringe or IV bag.
That means a patient comparing clinics solely on price and volume may be comparing the wrong things.
2. Where You Put the Treatment Matters
Gross discusses intravenous delivery, local injections, nasal delivery, and other routes—but emphasizes that anatomy and treatment goals matter.
A degenerative knee is different from a shoulder.
A joint is different from the spine.
And a chronic inflammatory degenerative issue is different from an acute sports injury.
For orthopedic cases, Gross says he uses clinical examination and advanced MRI imaging to determine the specific structures he believes should be targeted.
3. Better Imaging May Change the Treatment Plan
One of the most practical takeaways from this episode involves MRI.
Gross prefers high-quality 3-Tesla MRI imaging and often requests STIR/inversion recovery sequences because they can highlight inflammatory changes in bone and surrounding structures that may not be as obvious on standard imaging.
That leads to an important sports rehab lesson:
Don’t just treat the MRI report. Correlate the imaging with where the patient hurts, how they move, and what limits performance.
4. Your Biology Influences Your Outcome
Two athletes can have nearly identical MRIs, receive similar procedures, and still respond completely differently.
Why?
Gross points to overall health, severity of degeneration, treatment targeting, lifestyle, smoking, nutrition, sleep, movement, and the patient’s ability to recover.
That’s where regenerative medicine begins overlapping with longevity medicine and human performance.
The injection may only be one piece.
Recovery also depends on the biological environment you’re asking to heal.
5. Regenerative Medicine Doesn’t Replace the Basics
This may be the least glamorous—and most important—part of the conversation.
Gross repeatedly comes back to:
Exercise.
Protein.
Strength training.
Sleep.
Nutrition.
Inflammation control.
Healthy metabolic function.
Near the end of the show, he says one of the biggest changes in his own thinking around longevity has been the importance of maintaining muscle through resistance training rather than relying only on cardiovascular exercise.
And if he could give people one non-drug strategy to improve the next 20 years of life?
Deep, restorative sleep.
A Few Things You Can Do Right Now
Before spending thousands of dollars on regenerative medicine, start with three simple steps.
Ask better questions.
Ask exactly what product is being used, where it comes from, what testing exists, and whether the clinic can provide a certificate of analysis.
Get your recovery basics in order.
Poor sleep, smoking, inactivity, inadequate protein, and poor metabolic health can all work against recovery.
Understand your diagnosis.
Don’t settle for “you have arthritis.” Ask where the degeneration is, whether it matches your symptoms, and what imaging actually shows.
Those three steps cost little—but may dramatically improve the quality of your medical decisions.
Why This Conversation Matters Now
Regenerative medicine is exploding.
Athletes want faster recovery.
Active adults want to avoid joint replacement.
Older patients want to maintain mobility.
And the longevity community is increasingly focused not simply on living longer—but on maintaining muscle, movement, cartilage, brain health, and physical independence for decades.
That demand has created incredible innovation.
It has also created marketing.
And those are not the same thing.
Dr. Gross makes one point especially clear near the end of the episode: if you’re considering exosomes, ask your physician about their experience, what they’re using, where it came from, and whether they can show you the testing behind it.
Being an informed patient may be just as important as choosing the latest technology.
What You’ll Learn
In the full conversation, we go much deeper into:
What exosomes actually are—and how they differ from stem cells
Why exosome particle count may matter more than treatment volume
PRP vs. stem cells vs. exosomes: how Dr. Gross thinks about each
Whether timing matters after an acute injury
Why some patients respond dramatically while others don’t
The role of advanced MRI in targeting treatment
Exosomes and osteoarthritis, joint degeneration, sports injuries, and chronic inflammation
Why Gross believes lifestyle and longevity medicine should be part of regenerative care
What MUSE cells may mean for the future of spinal disc regeneration
Why resistance training, muscle mass, and restorative sleep may matter more for longevity than most people realize
And perhaps the biggest question:
Are exosomes truly changing regenerative medicine—or are we still early enough that patients need to be cautious about what they’re being promised?
The science is moving quickly.
So is the marketing.
Knowing the difference matters.
For the full story and unfiltered conversation, listen/watch the Crackin’ Backs Podcast.